Sweeten PAMPs: Role of sugar complexed PAMPs in innate immunity and vaccine biology

Frontiers in Immunology

Volumn 4, Issue SEP, 2013, Pages

  Mahla, Ranjeet Singh ^a   Reddy, Madhava C ^b   Vijaya Raghava Prasad, D ^b   Kumar, Himanshu ^a,c  

^a INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH BHOPAL   (India)

^b YOGI VEMANA UNIVERSITY   (India)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Disease pathogenesis; Innate immunity; Innate sensors; Sugar associated PAMPs; Vaccinology

Indexed keywords

EID: 84885967021     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00248     Document Type: Review

References (195)

1. Lloyd DH, Viac J, Werling D, Reme CA, Gatto H. Role of sugars in surface microbe-host interactions and immune reaction modulation. Vet Dermatol (2007) 18:197-204. doi:10.1111/j.1365-3164.2007.00594.x.
2. Kolarich D, Lepenies B, Seeberger PH. Glycomics, glycoproteomics and the immune system. Curr Opin Chem Biol (2012) 16:214-20. doi:10.1016/j.cbpa.2011.12.006.
3. Rabinovich GA, Van Kooyk Y, Cobb BA. Glycobiology of immune responses. Ann N Y Acad Sci (2012) 1253:1-15. doi:10.1111/j.1749-6632.2012.06492.x.
4. Franchi L, Warner N, Viani K, Nunez G. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev (2009) 227:106-28. doi:10.1111/j.1600-065X.2008.00734.x.
5. Barber GN. Cytoplasmic DNA innate immune pathways. Immunol Rev (2011) 243:99-108. doi:10.1111/j.1600-065X.2011.01051.x.
6. Kato H, Takahasi K, Fujita T. RIG-I-like receptors: cytoplasmic sensors for non-self RNA. Immunol Rev (2011) 243:91-8. doi:10.1111/j.1600-065X.2011.01052.x.
7. Kumar S, Ingle H, Prasad DV, Kumar H. Recognition of bacterial infection by innate immune sensors. Crit Rev Microbiol (2013) 39:229-46. doi:10.3109/1040841X.2012.706249.
8. Plato A, Willment JA, Brown GD. C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways. Int Rev Immunol (2013) 32:134-56. doi:10.3109/08830185.2013.777065.
9. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 11:373-84. doi:10.1038/ni.1863.
10. Lim KH, Staudt LM. Toll-like receptor signaling. Cold Spring Harb Perspect Biol (2013) 5:a011247. doi:10.1101/cshperspect.a011247.
11. O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors-redefining innate immunity. Nat Rev Immunol (2013) 13:453-60. doi:10.1038/nri3446.
12. Oldenburg M, Kruger A, Ferstl R, Kaufmann A, Nees G, Sigmund A, et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science (2012) 337:1111-5. doi:10.1126/science.1220363.
13. Jin MS, Lee JO. Structures of the toll-like receptor family and its ligand complexes. Immunity (2008) 29:182-91. doi:10.1016/j.immuni.2008.07.007.
14. Gay NJ, Keith FJ. Drosophila Toll and Il-1 receptor. Nature (1991) 351:355-6. doi:10.1038/351355b0.
15. Botos I, Segal DM, Davies DR. The structural biology of Toll-like receptors. Structure (2011) 19:447-59. doi:10.1016/j.str.2011.02.004.
16. Heinrichs DE, Yethon JA, Whitfield C. Molecular basis for structural diversity in the core regions of the lipopolysaccharides of Escherichia coli and Salmonella enterica. Mol Microbiol (1998) 30:221-32. doi:10.1046/j.1365-2958.1998.01063.x.
17. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 282:2085-8. doi:10.1126/science.282.5396.2085.
18. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol (1999) 162:3749-52.
19. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med (1999) 189:1777-82. doi:10.1084/jem.189.11.1777.
20. Beutler B. Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol (2000) 12:20-6. doi:10.1016/S0952-7915(99)00046-1.
21. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan-and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem (1999) 274:17406-9. doi:10.1074/jbc.274.25.17406.
22. Triantafilou M, Manukyan M, Mackie A, Morath S, Hartung T, Heine H, et al. Lipoteichoic acid and toll-like receptor 2 internalization and targeting to the Golgi are lipid raft-dependent. J Biol Chem (2004) 279:40882-9. doi:10.1074/jbc. M400466200.
23. Knapp S, Von Aulock S, Leendertse M, Haslinger I, Draing C, Golenbock DT, et al. Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol (2008) 180:3478-84.
24. Bowdish DM, Sakamoto K, Kim MJ, Kroos M, Mukhopadhyay S, Leifer CA, et al. MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis. PLoS Pathog (2009) 5:e1000474. doi:10.1371/journal.ppat.1000474.
25. Campos MA, Almeida IC, Takeuchi O, Akira S, Valente EP, Procopio DO, et al. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol (2001) 167:416-23.
26. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol (1999) 163:3920-7.
27. Strohmeier GR, Fenton MJ. Roles of lipoarabinomannan in the pathogenesis of tuberculosis. Microbes Infect (1999) 1:709-17. doi:10.1016/S1286-4579(99)80072-0.
28. Underhill DM, Ozinsky A, Smith KD, Aderem A. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci U S A (1999) 96:14459-63. doi:10.1073/pnas.96.25.14459.
29. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A toll-like receptor recognizes bacterial DNA. Nature (2000) 408:740-5. doi:10.1038/35047123.
30. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med (2003) 198:513-20. doi:10.1084/jem.20030162.
31. Peter ME, Kubarenko AV, Weber AN, Dalpke AH. Identification of an N-terminal recognition site in TLR9 that contributes to CpG-DNA-mediated receptor activation. J Immunol (2009) 182:7690-7. doi:10.4049/jimmunol.0900819.
32. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (2001) 413:732-8. doi:10.1038/35099560.
33. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 3:196-200. doi:10.1038/ni758.
34. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis E, Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (2004) 303:1529-31. doi:10.1126/science.1093616.
35. Han XB, Li X, Yue SC, Anandaiah A, Hashem F, Reinach PS, et al. Epigenetic regulation of tumor necrosis factor alpha (TNF alpha) release in human macrophages by HIV-1 single-stranded RNA (ssRNA) is dependent on TLR8 signaling. J Biol Chem (2012) 287:13778-86. doi:10.1074/jbc. M112.342683.
36. Tanji H, Ohto U, Shibata T, Miyake K, Shimizu T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science (2013) 339:1426-9. doi:10.1126/science.1229159.
37. Yoneyama M, Fujita T. Function of RIG-I-like receptors in antiviral innate immunity. J Biol Chem (2007) 282:15315-8. doi:10.1074/jbc. R700007200.
38. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity (2005) 23:19-28. doi:10.1016/j.immuni.2005.04.010.
39. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature (2006) 441:101-5. doi:10.1038/nature04734.
40. Satoh T, Kato H, Kumagai Y, Yoneyama M, Sato S, Matsushita K, et al. LGP2 is a positive regulator of RIG-I-and MDA5-mediated antiviral responses. Proc Natl Acad Sci U S A (2010) 107:1512-7. doi:10.1073/pnas.0912986107.
41. Bruns AM, Pollpeter D, Hadizadeh N, Myong S, Marko JF, Horvath CM. ATP hydrolysis enhances RNA recognition and antiviral signal transduction by the innate immune sensor, laboratory of genetics and physiology 2 (LGP2). J Biol Chem (2013) 288:938-46. doi:10.1074/jbc. M112.424416.
42. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 314:994-7. doi:10.1126/science.1132505.
43. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science (2006) 314:997-1001. doi:10.1126/science.1132998.
44. Wang Y, Ludwig J, Schuberth C, Goldeck M, Schlee M, Li H, et al. Structural and functional insights into 5'-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nat Struct Mol Biol (2010) 17:781-7. doi:10.1038/nsmb.1863.
45. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol (2004) 5:730-7. doi:10.1038/ni1087.
46. Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity (2011) 34:680-92. doi:10.1016/j.immuni.2011.05.003.
47. Wu B, Peisley A, Richards C, Yao H, Zeng X, Lin C, et al. Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5. Cell (2013) 152:276-89. doi:10.1016/j.cell.2012.11.048.
48. Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, et al. The NLR gene family: a standard nomenclature. Immunity (2008) 28:285-7. doi:10.1016/j.immuni.2008.02.005.
49. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jehanno M, Viala J, et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science (2003) 300:1584-7. doi:10.1126/science.1084677.
50. McDonald C, Inohara N, Nunez G. Peptidoglycan signaling in innate immunity and inflammatory disease. J Biol Chem (2005) 280:20177-80. doi:10.1074/jbc. R500001200.
51. Kufer TA, Kremmer E, Adam AC, Philpott DJ, Sansonetti PJ. The pattern-recognition molecule Nod1 is localized at the plasma membrane at sites of bacterial interaction. Cell Microbiol (2008) 10:477-86.
52. Chamaillard M, Hashimoto M, Horie Y, Masumoto J, Qiu S, Saab L, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol (2003) 4:702-7. doi:10.1038/ni945.
53. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol (2011) 29:707-35. doi:10.1146/annurev-immunol-031210-101405.
54. Bauernfeind F, Hornung V. Of inflammasomes and pathogens-sensing of microbes by the inflammasome. EMBO Mol Med (2013) 5:814-26. doi:10.1002/emmm.201201771.
55. Faustin B, Lartigue L, Bruey JM, Luciano F, Sergienko E, Bailly-Maitre B, et al. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell (2007) 25:713-24. doi:10.1016/j.molcel.2007.01.032.
56. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature (2009) 458:514-8. doi:10.1038/nature07725.
57. Jones JW, Kayagaki N, Broz P, Henry T, Newton K, O'Rourke K, et al. Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis. Proc Natl Acad Sci U S A (2010) 107:9771-6. doi:10.1073/pnas.1003738107.
58. Kankkunen P, Teirila L, Rintahaka J, Alenius H, WolffH, Matikainen S. (1,3)-Beta-glucans activate both dectin-1 and NLRP3 inflammasome in human macrophages. J Immunol (2010) 184:6335-42. doi:10.4049/jimmunol.0903019.
59. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol (2010) 11:395-402. doi:10.1038/ni.1864.
60. Vazquez-Mendoza A, Carrero JC, Rodriguez-Sosa M. Parasitic infections: a role for C-type lectins receptors. Biomed Res Int (2013) 2013:456352. doi:10.1155/2013/456352.
61. Vautier S, MacCallum DM, Brown GD. C-type lectin receptors and cytokines in fungal immunity. Cytokine (2012) 58:89-99. doi:10.1016/j.cyto.2011.08.031.
62. Pluddemann A, Mukhopadhyay S, Gordon S. The interaction of macrophage receptors with bacterial ligands. Expert Rev Mol Med (2006) 8:1-25. doi:10.1017/S1462399406000159.
63. Lambert AA, Gilbert C, Richard M, Beaulieu AD, Tremblay MJ. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans-and cis-infection pathways. Blood (2008) 112:1299-307. doi:10.1182/blood-2008-01-136473.
64. Osorio F, Reis e Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity (2011) 34:651-64. doi:10.1016/j.immuni.2011.05.001.
65. Redelinghuys P, Brown GD. Inhibitory C-type lectin receptors in myeloid cells. Immunol Lett (2011) 136:1-12. doi:10.1016/j.imlet.2010.10.005.
66. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol (2009) 9:465-79. doi:10.1038/nri2569.
67. Zelensky AN, Gready JE. The C-type lectin-like domain superfamily. FEBS J (2005) 272:6179-217. doi:10.1111/j.1742-4658.2005.05031.x.
68. Huysamen C, Brown GD. The fungal pattern recognition receptor, Dectin-1, and the associated cluster of C-type lectin-like receptors. FEMS Microbiol Lett (2009) 290:121-8. doi:10.1111/j.1574-6968.2008.01418.x.
69. Kerscher B, Willment JA, Brown GD. The Dectin-2 family of C-type lectin-like receptors: an update. Int Immunol (2013) 25:271-7. doi:10.1093/intimm/dxt006.
70. Brown GD, Gordon S. Immune recognition-a new receptor for beta-glucans. Nature (2001) 413:36-7. doi:10.1038/35092620.
71. Dennehy KM, Brown GD. The role of the beta-glucan receptor Dectin-1 in control of fungal infection. J Leukoc Biol (2007) 82:253-8. doi:10.1189/jlb.1206753.
72. Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, Findon H, et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol (2007) 8:31-8. doi:10.1038/ni1408.
73. Saijo S, Ikeda S, Yamabe K, Kakuta S, Ishigame H, Akitsu A, et al. Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity (2010) 32:681-91. doi:10.1016/j.immuni.2010.05.001.
74. Wells CA, Salvage-Jones JA, Li X, Hitchens K, Butcher S, Murray RZ, et al. The macrophage-inducible C-type lectin, Mincle, is an essential component of the innate immune response to Candida albicans. J Immunol (2008) 180:7404-13.
75. Lobato-Pascual A, Saether PC, Dahle MK, Gaustad P, Dissen E, Fossum S, et al. Rat macrophage C-type lectin is an activating receptor expressed by phagocytic cells. PLoS ONE (2013) 8:e57406. doi:10.1371/journal.pone.0057406.
76. Miyake Y, Toyonaga K, Mori D, Kakuta S, Hoshino Y, Oyamada A, et al. C-type lectin MCL is an FcRgamma-coupled receptor that mediates the adjuvanticity of mycobacterial cord factor. Immunity (2013) 38:1050-62. doi:10.1016/j.immuni.2013.03.010.
77. Ishikawa T, Itoh F, Yoshida S, Saijo S, Matsuzawa T, Gonoi T, et al. Identification of distinct ligands for the C-type lectin receptors Mincle and Dectin-2 in the pathogenic fungus Malassezia. Cell Host Microbe (2013) 13:477-88. doi:10.1016/j.chom.2013.03.008.
78. Zhang P, Snyder S, Feng P, Azadi P, Zhang SS, Bulgheresi S, et al. Role of N-acetylglucosamine within core lipopolysaccharide of several species of gram-negative bacteria in targeting the DC-SIGN (CD209). J Immunol (2006) 177:4002-11.
79. Turville S, Wilkinson J, Cameron P, Dable J, Cunningham AL. The role of dendritic cell C-type lectin receptors in HIV pathogenesis. J Leukoc Biol (2003) 74:710-8. doi:10.1189/jlb.0503208.
80. Ludwig IS, Lekkerkerker AN, Depla E, Bosman F, Musters RJ, Depraetere S, et al. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J Virol (2004) 78:8322-32. doi:10.1128/JVI.78.15.8322-8332.2004.
81. Cheong C, Matos I, Choi JH, Dandamudi DB, Shrestha E, Longhi MP, et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell (2010) 143:416-29. doi:10.1016/j.cell.2010.09.039.
82. Zhao LJ, Wang W, Ren H, Qi ZT. Interaction of L-SIGN with hepatitis C virus envelope protein E2 up-regulates Raf-MEK-ERK pathway. Cell Biochem Biophys (2013) 66:589-97. doi:10.1007/s12013-012-9505-4.
83. Svajger U, Anderluh M, Jeras M, Obermajer N. C-type lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity. Cell Signal (2010) 22:1397-405. doi:10.1016/j.cellsig.2010.03.018.
84. Brummer E, Stevens DA. Collectins and fungal pathogens: roles of surfactant proteins and mannose binding lectin in host resistance. Med Mycol (2010) 48:16-28. doi:10.3109/13693780903117473.
85. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol (2004) 4:499-511. doi:10.1038/nri1391.
86. Kondo T, Kawai T, Akira S. Dissecting negative regulation of Toll-like receptor signaling. Trends Immunol (2012) 33:449-58. doi:10.1016/j.it.2012.05.002.
87. Chen Y, Liu W, Sun T, Huang Y, Wang Y, Deb DK, et al. 1,25-Dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting microRNA-155-SOCS1 in macrophages. J Immunol (2013) 190:3687-95. doi:10.4049/jimmunol.1203273.
88. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. IPS-1, an adaptor triggering RIG-I-and Mda5-mediated type I interferon induction. Nat Immunol (2005) 6:981-8. doi:10.1038/ni1243.
89. Kumar H, Kawai T, Kato H, Sato S, Takahashi K, Coban C, et al. Essential role of IPS-1 in innate immune responses against RNA viruses. J Exp Med (2006) 203:1795-803. doi:10.1084/jem.20060792.
90. Kaji R, Kiyoshima-Shibata J, Nagaoka M, Nanno M, Shida K. Bacterial teichoic acids reverse predominant IL-12 production induced by certain Lactobacillus strains into predominant IL-10 production via TLR2-dependent ERK activation in macrophages. J Immunol (2010) 184:3505-13. doi:10.4049/jimmunol.0901569.
91. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci (2008) 1143:1-20. doi:10.1196/annals.1443.020.
92. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol (2009) 21:317-37. doi:10.1093/intimm/dxp017.
93. Bruns AM, Horvath CM. Activation of RIG-I-like receptor signal transduction. Crit Rev Biochem Mol Biol (2012) 47:194-206. doi:10.3109/10409238.2011.630974.
94. Suthar MS, Diamond MS, Gale M Jr. West Nile virus infection and immunity. Nat Rev Microbiol (2013) 11:115-28. doi:10.1038/nrmicro2950.
95. Dixit E, Boulant S, Zhang Y, Lee AS, Odendall C, Shum B, et al. Peroxisomes are signaling platforms for antiviral innate immunity. Cell (2010) 141:668-81. doi:10.1016/j.cell.2010.04.018.
96. Takahashi K, Kawai T, Kumar H, Sato S, Yonehara S, Akira S. Roles of caspase-8 and caspase-10 in innate immune responses to double-stranded RNA. J Immunol (2006) 176:4520-4.
97. Michallet MC, Meylan E, Ermolaeva MA, Vazquez J, Rebsamen M, Curran J, et al. TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity (2008) 28:651-61. doi:10.1016/j.immuni.2008.03.013.
98. Arimoto K, Takahashi H, Hishiki T, Konishi H, Fujita T, Shimotohno K. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. Proc Natl Acad Sci U S A (2007) 104:7500-5. doi:10.1073/pnas.0611551104.
99. Eisenacher K, Krug A. Regulation of RLR-mediated innate immune signaling-it is all about keeping the balance. Eur J Cell Biol (2012) 91:36-47. doi:10.1016/j.ejcb.2011.01.011.
100. Xu L, Xiao N, Liu F, Ren H, Gu J. Inhibition of RIG-I and MDA5-dependent antiviral response by gC1qR at mitochondria. Proc Natl Acad Sci U S A (2009) 106:1530-5. doi:10.1073/pnas.0811029106.
101. Park JH, Kim YG, McDonald C, Kanneganti TD, Hasegawa M, Body-Malapel M, et al. RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J Immunol (2007) 178:2380-6.
102. Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Nunez G, et al. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J (2008) 27:373-83. doi:10.1038/sj.emboj.7601962.
103. Shaw PJ, LamkanfiM, Kanneganti TD. NOD-like receptor (NLR) signaling beyond the inflammasome. Eur J Immunol (2010) 40:624-7. doi:10.1002/eji.200940211.
104. Barber GN. Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr Opin Immunol (2011) 23:10-20. doi:10.1016/j.coi.2010.12.015.
105. Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, Alnemri ES. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem (2012) 287:36617-22. doi:10.1074/jbc. M112.407130.
106. Satoh T, Kambe N, Matsue H. NLRP3 activation induces ASC-dependent programmed necrotic cell death, which leads to neutrophilic inflammation. Cell Death Dis (2013) 4:e644. doi:10.1038/cddis.2013.169.
107. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature (2008) 456:264-8. doi:10.1038/nature07383.
108. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Forster I, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 34:213-23. doi:10.1016/j.immuni.2011.02.006.
109. Beynon V, Quintana FJ, Weiner HL. Activated human CD4+CD45RO+ memory T-cells indirectly inhibit NLRP3 inflammasome activation through downregulation of P2X7R signalling. PLoS ONE (2012) 7:e39576. doi:10.1371/journal.pone.0039576.
110. Mao K, Chen S, Chen M, Ma Y, Wang Y, Huang B, et al. Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Cell Res (2013) 23:201-12. doi:10.1038/cr.2013.6.
111. Chen S, Sun B. Negative regulation of NLRP3 inflammasome signaling. Protein Cell (2013) 4:251-8. doi:10.1007/s13238-013-2128-8.
112. Masters SL, Gerlic M, Metcalf D, Preston S, Pellegrini M, O'Donnell JA, et al. NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity (2012) 37:1009-23. doi:10.1016/j.immuni.2012.08.027.
113. Gringhuis SI, Den Dunnen J, Litjens M, Van Der Vlist M, Wevers B, Bruijns SC, et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nat Immunol (2009) 10:203-13. doi:10.1038/ni.1692.
114. Gringhuis SI, Wevers BA, Kaptein TM, Van Capel TM, Theelen B, Boekhout T, et al. Selective C-Rel activation via Malt1 controls anti-fungal T(H)-17 immunity by dectin-1 and dectin-2. PLoS Pathog (2011) 7:e1001259. doi:10.1371/journal.ppat.1001259.
115. Sancho D, Reis e Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol (2012) 30:491-529. doi:10.1146/annurev-immunol-031210-101352.
116. Xu S, Huo J, Lee KG, Kurosaki T, Lam KP. Phospholipase Cgamma2 is critical for Dectin-1-mediated Ca2+ flux and cytokine production in dendritic cells. J Biol Chem (2009) 284:7038-46. doi:10.1074/jbc. M806650200.
117. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature (2007) 448:501-5. doi:10.1038/nature06013.
118. Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature (2008) 451:725-9. doi:10.1038/nature06537.
119. Yang P, An H, Liu X, Wen M, Zheng Y, Rui Y, et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat Immunol (2010) 11:487-94. doi:10.1038/ni.1876.
120. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol (2010) 11:997-1004. doi:10.1038/ni.1932.
121. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature (2008) 455:674-8. doi:10.1038/nature07317.
122. Tsuchida T, Zou JA, Saitoh T, Kumar H, Abe T, Matsuura Y, et al. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. Immunity (2010) 33:765-76. doi:10.1016/j.immuni.2010.10.013.
123. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Rohl I, et al. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Nature (2013) 498:380-4. doi:10.1038/nature12306.
124. Civril F, Deimling T, De Oliveira Mann CC, Ablasser A, Moldt M, Witte G, et al. Structural mechanism of cytosolic DNA sensing by cGAS. Nature (2013) 498:332-37. doi:10.1038/nature12305.
125. Sun LJ, Wu JX, Du FH, Chen X, Chen ZJJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the Type I interferon pathway. Science (2013) 339:786-91. doi:10.1126/science.1232458.
126. Zhang Z, Yuan B, Bao M, Lu N, Kim T, Liu YJ. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol (2011) 12:959-65. doi:10.1038/ni.2091.
127. Zhang Z, Bao M, Lu N, Weng L, Yuan B, Liu YJ. The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA. Nat Immunol (2013) 14:172-8. doi:10.1038/ni.2492.
128. Kondo T, Kobayashi J, Saitoh T, Maruyama K, Ishii KJ, Barber GN, et al. DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A (2013) 110:2969-74. doi:10.1073/pnas.1222694110.
129. Yi AK, Yoon H, Park JE, Kim BS, Kim HJ, Martinez-Hernandez A. CpG DNA-mediated induction of acute liver injury in D-galactosamine-sensitized mice: the mitochondrial apoptotic pathway-dependent death of hepatocytes. J Biol Chem (2006) 281:15001-12. doi:10.1074/jbc. M601337200.
130. Zadeh M, Khan MW, Goh YJ, Selle K, Owen JL, Klaenhammer T, et al. Induction of intestinal pro-inflammatory immune responses by lipoteichoic acid. J Inflamm (Lond) (2012) 9:7. doi:10.1186/1476-9255-9-7.
131. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial-endotoxin. Annu Rev Immunol (1995) 13:437-57. doi:10.1146/annurev.iy.13.040195.002253.
132. Shapira L, Soskolne WA, Houri Y, Barak V, Halabi A, Stabholz A. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect Immun (1996) 64:825-8.
133. Nymark M, Pussinen PJ, Tuomainen AM, Forsblom C, Groop PH, Lehto M, et al. Serum lipopolysaccharide activity is associated with the progression of kidney disease in Finnish patients with Type 1 diabetes. Diabetes Care (2009) 32:1689-93. doi:10.2337/dc09-0467.
134. Cavallo T, Granholm NA. Bacterial lipopolysaccharide induces long-lasting IgA deficiency concurrently with features of polyclonal B cell activation in normal and in lupus-prone mice. Clin Exp Immunol (1991) 84:134-8.
135. Yamamoto Y, Harashima A, Saito H, Tsuneyama K, Munesue S, Motoyoshi S, et al. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J Immunol (2011) 186:3248-57. doi:10.4049/jimmunol.1002253.
136. Sarkar R, Mitra D, Chakrabarti S. HIV-1 gp120 protein downregulates Nef induced IL-6 release in immature dendritic cells through interplay of DC-SIGN. PLoS ONE (2013) 8:e59073. doi:10.1371/journal.pone.0059073.
137. Devhare PB, Chatterjee SN, Arankalle VA, Lole KS. Analysis of antiviral response in human epithelial cells infected with hepatitis E virus. PLoS ONE (2013) 8:e63793. doi:10.1371/journal.pone.0063793.
138. Medina RA, Stertz S, Manicassamy B, Zimmermann P, Sun X, Albrecht RA, et al. Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Sci Transl Med (2013) 5:187ra170. doi:10.1126/scitranslmed.3005996.
139. Demento SL, Siefert AL, Bandyopadhyay A, Sharp FA, Fahmy TM. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol (2011) 29:294-306. doi:10.1016/j.tibtech.2011.02.004.
140. Kaisho T. Pathogen sensors and chemokine receptors in dendritic cell subsets. Vaccine (2012) 30:7652-7. doi:10.1016/j.vaccine.2012.10.043.
141. Driscoll M, Hansen R, Ding C, Cramer DE, Yan J. Therapeutic potential of various beta-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biol Ther (2009) 8:214-21.
142. Lipinski T, Fitieh A, St Pierre J, Ostergaard HL, Bundle DR, Touret N. Enhanced immunogenicity of a tricomponent mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via Dectin-1 by incorporating beta-glucan. J Immunol (2013) 190:4116-28. doi:10.4049/jimmunol.1202937.
143. Pietrella D, Rachini A, Torosantucci A, Chiani P, Brown AJ, Bistoni F, et al. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine (2010) 28:1717-25. doi:10.1016/j.vaccine.2009.12.021.
144. Liu M, Machova E, Nescakova Z, Medovarska I, Clemons KV, Martinez M, et al. Vaccination with mannan protects mice against systemic aspergillosis. Med Mycol (2012) 50:818-28. doi:10.3109/13693786.2012.683539.
145. Johnson AG, Gaines S, Landy M. Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J Exp Med (1956) 103:225-46. doi:10.1084/jem.103.2.225.
146. Johnson AG, Tomai M, Solem L, Beck L, Ribi E. Characterization of a nontoxic monophosphoryl lipid A. Rev Infect Dis (1987) 9(Suppl 5):S512-6. doi:10.1093/clinids/9.Supplement_5.S512.
147. Zhong Z, Wei X, Qi B, Xiao W, Yang L, Wei Y, et al. A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice. Int J Pharm (2010) 399:156-62. doi:10.1016/j.ijpharm.2010.07.053.
148. ten Brinke A, Van Schijndel G, Visser R, De Gruijl TD, Zwaginga JJ, Van Ham SM. Monophosphoryl lipid A plus IFNgamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential. Cancer Immunol Immunother (2010) 59:1185-95. doi:10.1007/s00262-010-0843-z.
149. MacLeod MK, McKee AS, David A, Wang J, Mason R, Kappler JW, et al. Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc Natl Acad Sci U S A (2011) 108:7914-9. doi:10.1073/pnas.1104588108.
150. Roy A, Chandra S, Mamilapally S, Upadhyay P, Bhaskar S. Anticancer and immunostimulatory activity by conjugate of paclitaxel and non-toxic derivative of LPS for combined chemo-immunotherapy. Pharm Res (2012) 29:2294-309. doi:10.1007/s11095-012-0756-y.
151. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE (2011) 6:e16333. doi:10.1371/journal.pone.0016333.
152. Baker PJ, Fauntleroy MB, Stashak PW, Hiernaux JR, Cantrell JL, Rudbach JA. Adjuvant effects of trehalose dimycolate on the antibody response to type III pneumococcal polysaccharide. Infect Immun (1989) 57:912-7.
153. Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun (2004) 72:1608-17. doi:10.1128/IAI.72.3.1608-1617.2004.
154. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y, et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta (2005) 1718:22-31. doi:10.1016/j.bbamem.2005.10.011.
155. Henriksen-Lacey M, Devitt A, Perrie Y. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release (2011) 154:131-7. doi:10.1016/j.jconrel.2011.05.019.
156. Desel C, Werninghaus K, Ritter M, Jozefowski K, Wenzel J, Russkamp N, et al. The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling. PLoS ONE (2013) 8:e53531. doi:10.1371/journal.pone.0053531.
157. Schweneker K, Gorka O, Schweneker M, Poeck H, Tschopp J, Peschel C, et al. The mycobacterial cord factor adjuvant analogue trehalose-6,6'-dibehenate (TDB) activates the Nlrp3 inflammasome. Immunobiology (2013) 218:664-73. doi:10.1016/j.imbio.2012.07.029.
158. Colavecchia SB, Jolly A, Fernandez B, Fontanals AM, Fernandez E, Mundo SL. Effect of lipoarabinomannan from Mycobacterium avium subsp avium in Freund's incomplete adjuvant on the immune response of cattle. Braz J Med Biol Res (2012) 45:139-46. doi:10.1590/S0100-879X2012007500012.
159. Halassy B, Krstanovic M, Frkanec R, Tomasic J. Adjuvant activity of peptidoglycan monomer and its metabolic products. Vaccine (2003) 21:971-6. doi:10.1016/S0264-410X(02)00547-9.
160. Capparelli R, Nocerino N, Medaglia C, Blaiotta G, Bonelli P, Iannelli D. The Staphylococcus aureus peptidoglycan protects mice against the pathogen and eradicates experimentally induced infection. PLoS ONE (2011) 6:e28377. doi:10.1371/journal.pone.0028377.
161. Habjanec L, Frkanec R, Halassy B, Tomasic J. Effect of liposomal formulations and immunostimulating peptidoglycan monomer (PGM) on the immune reaction to ovalbumin in mice. J Liposome Res (2006) 16:1-16. doi:10.1080/08982100500528537.
162. Himanen JP, Pyhala L, Olander RM, Merimskaya O, Kuzina T, Lysyuk O, et al. Biological-activities of lipoteichoic acid and peptidoglycan teichoic-acid of Bacillus-subtilis-168 (Marburg). J Gen Microbiol (1993) 139:2659-65. doi:10.1099/00221287-139-11-2659.
163. Okamoto M, Ohe G, Oshikawa T, Furuichi S, Nishikawa H, Tano T, et al. Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus. Cancer Immunol Immunother (2001) 50:408-16. doi:10.1007/s002620100207.
164. Martins VP, Pinheiro CS, Figueiredo BC, Assis NR, Morais SB, Caliari MV, et al. Vaccination with enzymatically cleaved GPI-anchored proteins from Schistosoma mansoni induces protection against challenge infection. Clin Dev Immunol (2012) 2012:962538. doi:10.1155/2012/962538.
165. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. Cpg motifs in bacterial-DNA trigger direct B-cell activation. Nature (1995) 374:546-9. doi:10.1038/374546a0.
166. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A (1996) 93:2879-83. doi:10.1073/pnas.93.7.2879.
167. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines (2011) 10:499-511. doi:10.1586/erv.10.174.
168. Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol (2012) 12:479-91. doi:10.1038/nri3247.
169. Dalpke AH, Zimmermann S, Albrecht I, Heeg K. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology (2002) 106:102-12. doi:10.1046/j.1365-2567.2002.01410.x.
170. Wu CC, Lee J, Raz E, Corr M, Carson DA. Necessity of oligonucleotide aggregation for toll-like receptor 9 activation. J Biol Chem (2004) 279:33071-8. doi:10.1074/jbc. M311662200.
171. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol (2001) 31:2154-63. doi:10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U.
172. Marshall JD, Fearon KL, Higgins D, Hessel EM, Kanzler H, Abbate C, et al. Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol (2005) 24:63-72. doi:10.1089/dna.2005.24.63.
173. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev (2009) 61:195-204. doi:10.1016/j.addr.2008.12.008.
174. Davis HL, Weeranta R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol (1998) 160:870-6.
175. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A (1997) 94:10833-7. doi:10.1073/pnas.94.20.10833.
176. Angel JB, Cooper CL, Clinch J, Young CD, Chenier A, Parato KG, et al. CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. J Immune Based Ther Vaccines (2008) 6:4. doi:10.1186/1476-8518-6-4.
177. Jeske S, Pries R, Wollenberg B. CpG-induced IFN-alpha production of plasmacytoid dendritic cells: time and dosage dependence and the effect of structural modifications to the CpG backbone. Nucleic Acid Ther (2013) 23:118-24. doi:10.1089/nat.2012.0384.
178. Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol (2006) 25:135-54. doi:10.1080/08830180600743057.
179. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity (2010) 33:492-503. doi:10.1016/j.immuni.2010.10.002.
180. Ato M, Takahashi Y, Fujii H, Hashimoto S, Kaji T, Itamura S, et al. Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-alpha-dependent apoptosis. Vaccine (2013) 31:2184-90. doi:10.1016/j.vaccine.2013.02.016.
181. Geeraedts F, Goutagny N, Hornung V, Severa M, De Haan A, Pool J, et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog (2008) 4:e1000138. doi:10.1371/journal.ppat.1000138.
182. Chakravarthy KV, Bonoiu AC, Davis WG, Ranjan P, Ding H, Hu R, et al. Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. Proc Natl Acad Sci U S A (2010) 107:10172-7. doi:10.1073/pnas.0914561107.
183. Wong JP, Saravolac EG, Sabuda D, Levy HB, Kende M. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob Agents Chemother (1995) 39:2574-6. doi:10.1128/AAC.39.11.2574.
184. Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, et al. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine (2010) 28:7256-66. doi:10.1016/j.vaccine.2010.08.098.
185. Chen H, Chuai X, Deng Y, Wen B, Wang W, Xiong S, et al. Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine. PLoS ONE (2012) 7:e43730. doi:10.1371/journal.pone.0043730.
186. Chuai X, Chen H, Wang W, Deng Y, Wen B, Ruan L, et al. Poly(I:C)/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boosting. PLoS ONE (2013) 8:e54126. doi:10.1371/journal.pone.0054126.
187. Thim HL, Iliev DB, Christie KE, Villoing S, McLoughlin MF, Strandskog G, et al. Immunoprotective activity of a Salmonid Alphavirus vaccine: comparison of the immune responses induced by inactivated whole virus antigen formulations based on CpG class B oligonucleotides and poly I:C alone or combined with an oil adjuvant. Vaccine (2012) 30:4828-34. doi:10.1016/j.vaccine.2012.05.010.
188. Scallan CD, Tingley DW, Lindbloom JD, Toomey JS, Tucker SN. An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol (2013) 20:85-94. doi:10.1128/CVI.00552-12.
189. Lepenies B, Lee J, Sonkaria S. Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv Drug Deliv Rev (2013). doi:10.1016/j.addr.2013.05.007.
190. Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials (2012) 33:4229-39. doi:10.1016/j.biomaterials.2012.02.036.
191. Garcia-Vallejo JJ, Unger WWJ, Kalay H, Van Kooyk Y. Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines. Oncoimmunology (2013) 2(2):e23040. doi:10.4161/onci.23040.
192. van Kooyk Y, Unger WW, Fehres CM, Kalay H, Garcia-Vallejo JJ. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol Immunol (2013) 55:143-5. doi:10.1016/j.molimm.2012.10.031.
193. Ribeiro-Viana R, Sanchez-Navarro M, Luczkowiak J, Koeppe JR, Delgado R, Rojo J, et al. Virus-like glycodendrinanoparticles displaying quasi-equivalent nested polyvalency upon glycoprotein platforms potently block viral infection. Nat Commun (2012) 3:1303. doi:10.1038/ncomms2302.
194. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity (1999) 11:443-51. doi:10.1016/S1074-7613(00)80119-3.
195. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol (2005) 175:2851-8.